Strongly linked to secondary hyperparathyroidism, renal osteodystrophy, and vascular and soft tissue calcification, hyperphosphataemia if left uncontrolled can lead to increased cardiovascular mortality in patients with end-stage renal disease. According to some studies, adjusted mortality increases by 20%-40% with increases in serum phosphate levels (up to 4.2 mmol/L).
INTRODUCTION
Strongly linked to secondary hyperparathyroidism, renal osteodystrophy, and vascular and soft tissue calcification, hyperphosphataemia if left uncontrolled can lead to increased cardiovascular mortality in patients with end-stage renal disease. According to some studies, adjusted mortality increases by 20%-40% with increases in serum phosphate levels (up to 4.2 mmol/L). (1, 2) Calcium levels are also commonly raised as a result of hyperparathyroidism, and this together with hyperphosphataemia can increase the calcium-phosphate product, which is an independent factor for cardiac mortality.
Calcium-based phosphate binders have been used in medical practice for many years, although they can increase serum calcium levels and therefore predispose patients to vascular and cardiac calcifications. (4) Likewise, although aluminium-containing agents are highly effective, they are related to accumulation and toxicity. (5) Lanthanum carbonate is an alternative non-calciumbased binder that has promising phosphate-binding effects.
However, long-term data on the safety and coronary calcification of lanthanum are still under debate. (6) Sevelamer hydrochloride (Renagel) is non-metal-based and frequently used as a secondline phosphate binder in patients on renal replacement therapy.
Several randomised controlled studies have shown that sevelamer can reduce serum calcium levels and the incidence of hypercalcaemia. (7) (8) (9) These studies have also shown that sevelamer is equipotent to calcium-based phosphate binders in reducing serum phosphate levels. Although many small studies have confirmed sevelamer's effects on slowing coronary calcifications in both dialysis and predialysis patients, there are still no long-term data that support the use of sevelamer over other phosphate-binding agents in the reduction of mortality. (10, 11) According to some authors, treatment with sevelamer can also reduce all-cause hospitalisations as compared to treatment with calcium-based binders. (12) In addition to the phosphate-reducing and calcium-sparing properties of sevelamar, many small studies have shown that its use is linked to improvements in serum uric acid, low-density lipoprotein (LDL) cholesterol and C-reactive protein levels. (13) (14) (15) As sevelamer is not absorbed by the gastrointestinal tract, it has a relatively low incidence of side effects. It also has the ability to bind and sequester bile acid, which may explain its lipid-lowering effect. (4) It has also been postulated that sevelamer decreases serum uric acid concentration in maintenance haemodialysis patients through the adsorption of uric acid. (16) 
METHODS
This was a retrospective study that included all patients on renal replacement therapy (between 2008 and 2011) who had previously received calcium-based binders for ≥ 6 months and were subsequently switched to sevelamer. Data collected from the patients' medical records included demographics, as well as renal parameters three months prior to sevelamer treatment, and at three and six months post treatment. The study excluded patients on multiple, concomitant phosphate binders or with functioning renal transplants, and those who were noncompliant or had inadequate follow-up blood investigations.
countries, probably due to its high cost and differences in regional marketing policies.
The main objectives of this study were to assess: (a) the efficacy of sevelamer against calcium-based phosphate binders, in terms of its effects on serum phosphate, calcium, parathyroid hormone, bicarbonate, uric acid and lipid levels; and (b) its tolerability and side-effect profile. Our study aimed to provide new information on the efficacy and tolerability of sevelamer in a dialysis population predominantly composed of patients of Malay ethnicity.
ME THODS
This was a retrospective study that assessed the effects of sevelamer in patients on renal replacement therapy who had previously received calcium-based phosphate binders for Target renal parameters at three months pre-sevelamer treatment (or at baseline if patients were on calcium-based phosphate binders), and at three and six months post-sevelamer treatment were compared. Differences between pairs were calculated using Student's t-test. Two-tailed p < 0.05 was considered statistically significant.
RESULTS
A total of 39 patients were included in the study. was not documented. The serum levels of various biochemical parameters at three months pre-sevelamer treatment, and at three and six months post-sevelamer treatment, are presented in Table II . There was significant improvement in the calcium, phosphate, uric acid and LDL cholesterol levels of the patients at three and six months post-sevelamer treatment. Table III presents the number of patients in whom reduced, unchanged or increased biochemical parameters were seen at three and six months post-sevelamer treatment, respectively.
DISCUSSION
A search of the published literature listed in PubMed's database revealed that few studies had reported on the efficacy of sevelamer in Asian patients of non-Japanese descent.
A summary of studies on sevelamer from Taiwan, Hong Kong, India and Saudi Arabia is presented in Table IV . (17) (18) (19) (20) (21) (22) A majority of these studies compared the efficacy of calcium-based binders and sevelamer with regard to bone turnover. The consensus is that sevelamer is as good as calcium-based binders in reducing phosphate, but superior to calcium-based binders in reducing hypercalcaemia. Studies from Hong Kong have shown that sevelamer was cost-effective at lower doses and effective in patients with severe hyperphosphataemia. (19, 20) Our study is thus the first of its kind reporting the efficacy of sevelamer treatment in an Asian population composed primarily of patients of Malay ethnicity on renal replacement therapy.
Similar to other Asian studies, we also found a reduction in calcium and calcium-phosphate products following sevelamer treatment when compared to treatment with calcium-based phosphate binders. Compared with calcium-based binders, sevelamer also appeared to have significantly better phosphate-reducing properties. Our results are particularly significant, as many of our patients already had advanced renal bone disease with high serum calcium and phosphate levels that were unresponsive to therapy with calcium-containing binders. A trend toward better lipid and uric acid control was also observed in patients after sevelamer treatment. Expectedly, due to its hydrochloride content, the use of sevelamer was associated with lower serum logically expect an increase in parathyroid hormone levels at follow-up six months post-sevelamer treatment due to the expected progression of renal bone disease. However, judging by the stable parathyroid hormone levels seen at six months post-sevelamer treatment in our cohort, we speculate that the low calcium and phosphate levels observed following six months of sevelamer treatment had enabled more vitamin D to be used, thus maintaining a stable parathyroid status.
No major side effects were reported by our patients, with only three reporting mild gastrointestinal disturbances, although many patients reported that sevelamer tablets were more difficult to swallow, as they were bigger than calcium-based binders.
Despite this, the inconvenience caused was not severe enough for any of our patients to discontinue medication or revert to calcium-based binders. However, it is also possible that some patients may not have been entirely truthful about the drug's side effects. This can be attributed to the conservative, noncritical nature of Brunein culture, which might have led our cohort to be reluctant to reveal all the side effects experienced. Some participants might have also been ignorant of the medication they were prescribed and the accompanying side effects.
Given these factors, a prospective trial involving a placebo group or with a crossover design might have been better for ascertaining the true side effects of the medication. We acknowledge that there are limitations to this study.
Most of our patients who were started on sevelamer already had advanced metabolic bone disorder, with high serum calcium, phosphate and parathyroid hormone levels. It is likely that the withdrawal of calcium-based binders in these patients (who were mostly secondary and tertiary hyperparathyroid patients) would have invariably led to a reduction in calcium levels regardless of the use of sevelamer. We were unable to justify using a crossover trial for these patients, as it would be unethical to discontinue sevelamer in patients with 'corrected' bone biochemistry, as many would have already tried the calcium-based formulations and found them to be ineffective.
We conclude that sevelamer is effective as a second-line agent in the control of hypercalcaemia and hyperphosphataemia in patients with advanced renal bone disease. Sevelamer may also play a role in delaying parathyroidectomy, as it allows for the incremental use of vitamin D derivatives to control tertiary hyperparathyroidism. We also observed a trend toward better lipid and uric acid control in patients receiving sevelamer.
Finally, we opine that more studies are needed in order to examine the effects of sevelamer as a first-line phosphate binder in patients with early renal bone disease.
